Business Description
Fresenius SE & Co KGaA
ISIN : DE0005785604
Share Class Description:
XTER:FRE: Ordinary SharesCompare
Compare
Traded in other countries / regions
FRE.Germany0OO9.UKFSNUY.USAFREN.Mexico1FRE.ItalyFRE.Austria IPO Date
1992-08-06Description
Fresenius SE is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain. Vamed provides a variety of services such as healthcare facility construction and operation management, including post-acute care rehabilitation.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.2 | |||||
| Equity-to-Asset | 0.44 | |||||
| Debt-to-Equity | 0.71 | |||||
| Debt-to-EBITDA | 4.65 | |||||
| Interest Coverage | 2.8 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 1.17 | |||||
| Beneish M-Score | -3.52 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -15.2 | |||||
| 3-Year EBITDA Growth Rate | -27.8 | |||||
| 3-Year EPS without NRI Growth Rate | -4.4 | |||||
| 3-Year FCF Growth Rate | -1.3 | |||||
| 3-Year Book Growth Rate | 3.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 12.26 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 2.75 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 57.98 | |||||
| 9-Day RSI | 62.7 | |||||
| 14-Day RSI | 64.72 | |||||
| 6-1 Month Momentum % | 27.8 | |||||
| 12-1 Month Momentum % | 7.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.29 | |||||
| Quick Ratio | 1 | |||||
| Cash Ratio | 0.29 | |||||
| Days Inventory | 65.9 | |||||
| Days Sales Outstanding | 76.2 | |||||
| Days Payable | 33.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Dividend Growth Rate | 3.2 | |||||
| 3-Year Average Share Buyback Ratio | -0.6 | |||||
| Shareholder Yield % | 68.59 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 23.25 | |||||
| Operating Margin % | 5.61 | |||||
| Net Margin % | -4.99 | |||||
| FCF Margin % | 12.24 | |||||
| ROE % | -5.71 | |||||
| ROA % | -1.96 | |||||
| ROIC % | 0.66 | |||||
| 3-Year ROIIC % | 13.99 | |||||
| ROC (Joel Greenblatt) % | 7.18 | |||||
| ROCE % | 3.13 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 10.22 | |||||
| PE Ratio without NRI | 13.2 | |||||
| Shiller PE Ratio | 10.14 | |||||
| PS Ratio | 0.87 | |||||
| PB Ratio | 1.02 | |||||
| Price-to-Tangible-Book | 11.54 | |||||
| Price-to-Free-Cash-Flow | 7.11 | |||||
| Price-to-Operating-Cash-Flow | 5.11 | |||||
| EV-to-EBIT | 22.58 | |||||
| EV-to-Forward-EBIT | 15.29 | |||||
| EV-to-EBITDA | 10.33 | |||||
| EV-to-Forward-EBITDA | 8.99 | |||||
| EV-to-Revenue | 1.35 | |||||
| EV-to-Forward-Revenue | 1.36 | |||||
| EV-to-FCF | 11.08 | |||||
| Price-to-Projected-FCF | 0.57 | |||||
| Price-to-Median-PS-Value | 1.12 | |||||
| Price-to-Graham-Number | 2.58 | |||||
| Earnings Yield (Greenblatt) % | 4.43 | |||||
| FCF Yield % | 14.27 | |||||
| Forward Rate of Return (Yacktman) % | -7.63 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Fresenius SE & Co KGaA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 22,360 | ||
| EPS (TTM) (€) | -1.98 | ||
| Beta | 1.19 | ||
| Volatility % | 37.78 | ||
| 14-Day RSI | 64.72 | ||
| 14-Day ATR (€) | 0.562448 | ||
| 20-Day SMA (€) | 33.3415 | ||
| 12-1 Month Momentum % | 7.11 | ||
| 52-Week Range (€) | 23.93 - 35.03 | ||
| Shares Outstanding (Mil) | 563.24 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Fresenius SE & Co KGaA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Fresenius SE & Co KGaA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Fresenius SE & Co KGaA Frequently Asked Questions
What is Fresenius SE & Co KGaA(XTER:FRE)'s stock price today?
The current price of XTER:FRE is €34.04. The 52 week high of XTER:FRE is €35.03 and 52 week low is €23.93.
When is next earnings date of Fresenius SE & Co KGaA(XTER:FRE)?
The next earnings date of Fresenius SE & Co KGaA(XTER:FRE) is 2024-11-06.
Does Fresenius SE & Co KGaA(XTER:FRE) pay dividends? If so, how much?
Fresenius SE & Co KGaA(XTER:FRE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers